While you analyze one ticker, A.I. is already three days ahead.
VantagePoint's patented A.I. processes thousands of intermarket correlations in milliseconds, forecasting price direction before it shows on any chart. That's up to 87.4% proven accuracy, backed by 35+ years of research.
In today's markets, manual analysis isn't just slower. It's losing.
The only question: are you using A.I., or competing against it?
Download your free guide and find out how to put it to work for your retirement portfolio.
Braze (BRZE) reported earnings of $0.10 per share on revenue of $205.17 million for the fiscal fourth quarter ended January 2026. The consensus earnings estimate was $0.14 per share on revenue of $198.19 million. The Earnings Whisper number was $0.15 per share. The company missed expectations by 33.33% while revenue grew 27.91% on a year-over-year basis.
The company said it expects first quarter non-GAAP earnings of $0.10 to $0.11 per share on revenue of $204.5 million to $205.5 million. The current consensus earnings estimate is $0.12 per share on revenue of $197.70 million for the quarter ending April 30, 2026. The company also said it expects fiscal year non-GAAP earnings of $0.61 to $0.65 per share on revenue of $884.0 million to $889.0 million. The current consensus earnings estimate is $0.64 per share on revenue of $857.81 million for the year ending January 31, 2027.
Braze is a leading comprehensive customer engagement platform that powers interactions between consumers and brands they love.
Positive Guidance
AAR Guides Above Estimates
AAR Corp. (AIR) said it expects fourth quarter revenue of $897.86 million to $912.95 million. The current consensus revenue estimate is $862.00 million for the quarter ending May 31, 2026.
AAR Corp along with its subsidiaries is engaged in providing products & services including overhaul, repair & engineering services to aviation & government & defense markets. It is also engaged in design, manufacture, & repair of transportation pallets.
MaxCyte, Inc (MXCT) said it expects 2026 revenue of $30.0 million to $32.0 million. The current consensus revenue estimate is $37.75 million for the year ending December 31, 2026.
MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies.
NRx Pharmaceuticals (NRXP) reported earnings of $0.19 per share on revenue of $0.98 million for the fourth quarter ended December 2025. The consensus estimate was a loss of $0.09 per share on revenue of $6.30 million. The company beat consensus estimates by 311.11%.
NRX Pharmaceuticals Inc. is a patient-focused, clinical stage pharmaceutical company. It creates therapies to treat diseases where no medicines currently exist. NRX Pharmaceuticals Inc., formerly known as Big Rock Partners Acquisition Corp., is based in RADNOR, Pa.
Fennec Pharmaceuticals (FENC) reported a loss of $0.11 per share on revenue of $13.78 million for the fourth quarter ended December 2025. The consensus earnings estimate was $0.03 per share on revenue of $14.97 million. The company missed consensus estimates by 466.67% while revenue grew 73.84% on a year-over-year basis.
Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The Company's products include Eniluracil and Sodium Thiosulfate (STS). Fennec Pharmaceuticals Inc., formerly known as Adherex Technologies Inc., is based in United States.
Beyond Meat is Expected to Miss Estimates
Beyond Meat (BYND) is confirmed to report earnings on Wednesday, March 25, 2026 at approximately 5:40 PM ET. The consensus estimate is a loss of $0.12 per share on revenue of $67.85 million, a decline of 11.5% year-over-year, and the Earnings Whisper ® number is a loss of $0.15 per share. Investors are 8.7% bullish going into the company's earnings release. Option traders are pricing in a 41.0% move on earnings and the stock has averaged a 8.6% move in recent quarters.
Braze (BRZE) reported earnings of $0.10 per share on revenue of $205.17 million for the fiscal fourth quarter ended January 2026. The consensus earnings estimate was $0.14 per share on revenue of $198.19 million. The Earnings Whisper number was $0.15 per share. The company missed expectations by 33.33% while revenue grew 27.91% on a year-over-year basis.
AAR Corp. (
MaxCyte, Inc (
NRx Pharmaceuticals (NRXP) reported earnings of $0.19 per share on revenue of $0.98 million for the fourth quarter ended December 2025. The consensus estimate was a loss of $0.09 per share on revenue of $6.30 million. The company beat consensus estimates by 311.11%.
Fennec Pharmaceuticals (FENC) reported a loss of $0.11 per share on revenue of $13.78 million for the fourth quarter ended December 2025. The consensus earnings estimate was $0.03 per share on revenue of $14.97 million. The company missed consensus estimates by 466.67% while revenue grew 73.84% on a year-over-year basis.
Beyond Meat (BYND) is confirmed to report earnings on Wednesday, March 25, 2026 at approximately 5:40 PM ET. The consensus estimate is a loss of $0.12 per share on revenue of $67.85 million, a decline of 11.5% year-over-year, and the Earnings Whisper ® number is a loss of $0.15 per share. Investors are 8.7% bullish going into the company's earnings release. Option traders are pricing in a 41.0% move on earnings and the stock has averaged a 8.6% move in recent quarters.